Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma

NCT01460602 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Investigator has relocated to MD Anderson

Conditions

Follicular Lymphoma
Marginal Zone Lymphoma
Mantle Cell Lymphoma

Interventions

DRUG: MTD of Velcade, Nipent and Rituxan established in Part 1

Sponsor

Louisiana State University Health Sciences Center Shreveport

Collaborators

[object Object]